Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Revenue | $168M | — |
| Operating income | $57.6M | -$143M |
| Operating margin | 34.4% | — |
| Net income | $52.2M | -$131M |
| Net margin | 31.2% | — |
| EPS (diluted) | $1.25 | -$3.05 |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Operating cash flow | $76.0M | -$112M |
| Capital expenditures | $1.15M | $794K |
| Free cash flow | $74.8M | -$113M |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Cash & equivalents | $197M | $189M |
| Total assets | $241M | $397M |
| Total liabilities | $43.6M | $42.2M |
| Shareholders' equity | -$311M | $355M |
| Retained earnings | -$358M | -$490M |
| Shares (wtd avg diluted) | 2.73M | 43.0M |
Every figure is extracted from Maze Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.